YAP1-fusions in pediatric NF2-wildtype meningioma by Sievers, Philipp et al.








YAP1-fusions in pediatric NF2-wildtype meningioma
Sievers, Philipp ; Chiang, Jason ; Schrimpf, Daniel ; Stichel, Damian ; Paramasivam, Nagarajan ; Sill,
Martin ; et al ; Rushing, Elisabeth
DOI: https://doi.org/10.1007/s00401-019-02095-9





Sievers, Philipp; Chiang, Jason; Schrimpf, Daniel; Stichel, Damian; Paramasivam, Nagarajan; Sill, Mar-
tin; et al; Rushing, Elisabeth (2019). YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neu-
ropathologica, 139(1):215-218.
DOI: https://doi.org/10.1007/s00401-019-02095-9
YAP1-fusions in pediatric NF2-wildtype meningioma 1 
Philipp Sievers1,2, Jason Chiang3, Daniel Schrimpf1,2, Damian Stichel1,2, Nagarajan 2 
Paramasivam4, Martin Sill5,6, Tenzin Gayden7,8, Belen Casalini1,2, David E. Reuss1,2, James 3 
Dalton3, Kristian W. Pajtler5,6,9, Daniel Hänggi10, Christel Herold-Mende11, Elisabeth 4 
Rushing12, Andrey Korshunov1,2,5, Christian Mawrin13, Michael Weller14, Matthias Schlesner4, 5 
Wolfgang Wick15,16, Nada Jabado7,8, David T.W. Jones5,17, Stefan M. Pfister5,6,9, Andreas von 6 
Deimling1,2, David W. Ellison3, Felix Sahm1,2,5 7 
 8 
1Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany 9 
2Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer 10 
Research Center (DKFZ), Heidelberg, Germany 11 
3Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA 12 
4Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany 13 
5Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany 14 
6Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 15 
Heidelberg, Germany 16 
7Department of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada 17 
8Department of Pediatrics, McGill University, and The Research Institute of the McGill University Health Center, Montreal, QC,  18 
H4A 3J1, Canada 19 
9Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg, 20 
Germany 21 
10Department of Neurosurgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany 22 
11Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany 23 
12Institute of Neuropathology, University Hospital and University of Zurich, Zurich, Switzerland 24 
13Institute of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany 25 
14Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland 26 
15Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer 27 
Research Center (DKFZ), Heidelberg, Germany 28 
16Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, 29 
Heidelberg, Germany 30 
17Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany 31 
 32 
Corresponding author: 33 
Felix Sahm, MD, PhD 34 
Department of Neuropathology  35 
University Hospital Heidelberg 36 
69120 Heidelberg, Germany 37 
Fon: +49-6221 56-37886 38 
Fax: +49-6221 56 4566 39 
felix.sahm@med.uni-heidelberg.de 40 
 41 
Key words: pediatric meningioma, molecular diagnostics, gene fusions, RNA sequencing, 42 
YAP1-MAML2, YAP1-PYGO1, YAP1- LMO1 43 
Word count:  44 
Main text 781, legend to figure in main manuscript 145 45 
Meningioma is the most common primary central nervous system (CNS) tumor [8]. In 1 
contrast to adulthood, meningiomas are rare among children and adolescents and frequently 2 
(about 38%) occur in the context of tumor predisposition syndromes [12]. In line with the 3 
frequent inactivation of NF2 in adult meningiomas, neurofibromatosis type 2 is the most 4 
common inherited syndrome predisposing to the early development of meningiomas, which 5 
are often multiple. Other germline alterations predisposing to meningioma development are 6 
SMARCE1 [14] and SUFU mutations [1]. More recently identified drivers of meningiomas 7 
include AKT1/TRAF7, SMO, KLF4/TRAF7, and PIK3CA mutations [3, 5]. 8 
The mutational underpinnings of sporadic pediatric meningioma have remained elusive to 9 
date. We report in-frame gene rearrangements predicted to result in fusions involving YAP1 10 
in nine meningiomas. We initially identified a YAP1-MAML2 fusion by clinical RNA 11 
sequencing in a four year old female patient with an intraventricular mass, histologically 12 
compatible with meningioma. Subsequently, based on our database of >30,000 DNA 13 
methylation profiles of brain tumors [4], including >1,000 meningiomas (among them about 14 
102 pediatric meningiomas, defined as age of diagnosis equal or below 18 years) [13], and 15 
corresponding copy number information, we additionally identified eight meningiomas with 16 
structural alterations affecting chromosome 11q around the YAP1 locus (Online Resources 17 
Supplementary Fig. 2 and 3). All clustered with reference meningioma cases in t-SNE 18 
analysis of DNA methylation data (Fig. 1a) and showed histological and 19 
immunohistochemical features of meningioma (Online Resource Supplementary Fig. 1), 20 
despite two being initially diagnosed as glioma. Interestingly, of the nine cases two were 21 
classified as transitional and two as atypical meningiomas - both subtypes which often carry 22 
NF2 mutations. With the presented case number and incomplete information on few 23 
samples, robust conclusions are, however, not derivable on subtype distribution. This 24 
limitation also applies to localizations. The clinicopathological characteristics are summarized 25 
in Table 1. RNA (seven samples) or exome (one sample) sequencing [15] revealed the 26 
presence of YAP1 fusions in all eight additional tumors (Fig. 1b-d and Online Resource 27 
Supplementary Table 1).  28 
Seven tumors harbored a rearrangement of YAP1-MAML2 involving exons 1-5 (n=5) or only 29 
in exon 1 (n=2) of YAP1 (NM_001130145) and exon 2-5 of MAML2 (NM_032427). YAP1-30 
MAML2 fusions were verified by fluorescence in situ hybridization (FISH) performed in two 31 
cases (Online Resource Supplementary Fig. 4). A YAP1-PYGO1 fusion was seen in a single 32 
case, containing exons 1-4 of YAP1 and exons 2-3 of PYGO1 (NM_015617). Additionally, a 33 
YAP1-LMO1 fusion was detected in another case involving exons 1-4 of YAP1 and exons 2-34 
4 of LMO1. Of note, seven of the additional eight patients were children or adolescents, 35 
whereas one patient was an adult. 36 
YAP1 is a transcriptional co-activator and downstream effector of the HIPPO pathway that 37 
acts mainly through TEAD family transcription factors and regulates expression of genes 38 
involved in cell proliferation and apoptosis [6, 7, 19, 20]. Deregulation of the HIPPO pathway 39 
via overexpression of YAP1, leading to tumorigenesis is a frequent event in human 40 
malignancies including meningiomas [2, 9]. Rearrangements involving the YAP1 gene have 41 
also recently been implicated as a driver in different types of cancer. Valouev et al. reported 42 
an in-frame gene fusion between YAP1 and MAML2 in nasopharyngeal carcinomas [16]. A 43 
similar fusion between YAP1 and MAMLD1 has been described in ependymoma [10, 11]. 44 
Both MAML2 and MAMLD1 are members of the Mastermind gene family and act as 45 
transcriptional co-activators of NOTCH signaling [17]. The YAP1-MAML2 rearrangement 46 
combines the transcriptional activation domain of MAML2 with the TEAD-binding domain of 47 
YAP1, which likely results in NOTCH-independent co-activation of TEAD-mediated HIPPO 1 
signaling [17]. While PYGO1 has been associated with different types of cancer, structural 2 
rearrangements including YAP1 and PYGO1 have not been reported to the best of our 3 
knowledge. Notably, PYGO1 also functions as a transcriptional co-activator in the Wnt 4 
pathway. LMO1 acts as a transcriptional regulator with a tumor-promoting activity, but its role 5 
in tumors has not been well studied. 6 
These alterations seem to act as an alternative to NF2 inactivation, since no NF2 alterations 7 
were detected in the present cohort. The NF2 gene product, the tumor suppressor merlin, 8 
functions upstream of the HIPPO pathway and there is growing evidence suggesting a 9 
functional link between NF2, YAP1 and activation of the HIPPO pathway [2, 18]. In line, 10 
YAP1 fusion positive meningiomas clustered closer to NF2 mutant cases than other pediatric 11 
meningiomas (Online Resource Supplementary Fig. 5). This observation parallels the 12 
virtually mutually exclusive alterations of NF2 and YAP1 in ependymoma. Since DNA 13 
methylation correlates with cell-of-origin, the proximity of YAP1- and NF2-altered cases in the 14 
clustering might indicate more similarities of their precursor cells compared to SMARCE1 15 
mutant meningiomas. However, the lack of AKT1, SMO, or KLF4/TRAF7 mutant pediatric 16 
meningiomas and the few SMARCE1 cases are limitations of this analysis.  17 
Our findings identify YAP1 fusions as a potential oncogenic driver in the development of 18 
meningiomas, predominantly in pediatric patients, and strengthen the hypothesis that 19 
deregulation of the HIPPO pathway is a central mechanism in meningioma tumorigenesis. 20 
Further studies in larger cohorts are needed to determine additional downstream functional 21 
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Figure legends 32 
Fig. 1 a) Unsupervised hierarchical clustering of DNA methylation profiles in nine YAP1-fused meningiomas 33 
(MNG_YAP1) alongside 128 well-characterized CNS neoplasms and control tissue shown in a two-dimensional 34 
representation of pairwise sample correlations using the 15,000 most variant probes by t-distributed stochastic 35 
neighbor embedding (t-SNE) dimensionality reduction. Reference methylation classes: ependymoma, posterior 36 
fossa group A (EPN_PFA), ependymoma, posterior fossa group B (EPN_PFB), ependymoma, RELA fusion 37 
(EPN_RELA), ependymoma, YAP fusion (EPN_YAP), subependymoma, posterior fossa (EPN_PF_SE), 38 
ependymoma, spinal (EPN_SPINE), subependymoma, spinal (EPN_SPINE_SE), subependymoma, 39 
supratentorial (EPN_ST_SE), meningioma (MNG), chordoma (CHORDM), melanoma (MELN), schwannoma 40 
(SCHW) and control tissue white matter (CONTROL). Schematic of the YAP1-MAML2 fusion involving exons 1-5 41 
of YAP1 and exons 2-5 of MAML (b), the YAP1-PYGO1 fusion involving exons 1-4 of YAP1 and exons 2-3 of 42 
MAML2 (c) and the YAP1-LMO1 fusion involving exons 1-4 of YAP1 and exons 2-4 of LMO1 (d). 43 
  44 
Table1 Clinicopathological characteristics of the YAP1-fused meningioma cohort 
Case # Age (years) Sex Tumor location 
Initial 
Diagnosis Genetic alteration 
1 4 F lateral ventricles, 3rd ventricle MNG YAP1:MAML2 
2 3 M temporal PXA YAP1:PYGO1 
3 1 M 3rd ventricle, lateral ventricle pHGG YAP1:MAML2 
4  2 M skull base MNG YAP1:MAML2 
5 36 M optic nerve MNG YAP1:MAML2 
6 8 F skull base (supra-/infratentorial) MNG YAP1:LMO1 
7 17 M cavernous sinus MNG YAP1:MAML2 
8 7 F parietal MNG YAP1:MAML2 
9 7 F frontal MNG YAP1:MAML2 
MNG – meningioma, PXA – pleomorphic xanthoastrocytoma, pHGG – pediatric high grade glioma, F – female, M –
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